Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2326 • 2019 ACR/ARP Annual Meeting
Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
Annelies Blanken¹, Rabia Agca ², Conny van der Laken ³ and Mike Nurmohamed ⁴, ¹Amsterdam Rheumatology and immunulogy Center location Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center location Amsterdam UMC location VU medical center, Amsterdam, Netherlands Antilles, ⁴Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, explained both by an increased prevalence of traditional CV risk factors and…
Abstract Number: 2344 • 2019 ACR/ARP Annual Meeting
Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Jonathan Amos¹, Jennifer Kendall ¹, Robyn Moran ², Megan Krause ³, Paul Schmidt ⁴, Chase Hall ⁵, Mark Hamblin ⁶ and Mehrdad Maz ⁷, ¹University of Kansas Medical Center, Division of Rheumatology, KANSAS CITY, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Kansas, KANSAS CITY, KS, ⁴University of Kansas Medical Center, Division of Rheumatology, Kansas City, ⁵University of Kansas Medical Center, Division of Pulmonary and Critical Care, KANSAS CITY, ⁶University of Kansas Medical Center, Division of Pulmonary and Critical Care, Kansas City, KS, ⁷The University of Kansas Medical Center, KANSAS CITY, KS
Background/Purpose: Interstitial lung disease (ILD) as an extra-articular manifestation of rheumatoid arthritis (RA) leads to significant morbidity and mortality. As data is limited, this study…
Abstract Number: 2372 • 2019 ACR/ARP Annual Meeting
Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry
Joel Kremer¹, Clifton Bingham ², Laura Cappelli ², Jeffrey Greenberg ³, Jamie Geier ⁴, Ann Madsen ⁴, Connie Chen ⁴, Alina Onofrei ⁵, Christine Barr ⁵, Dimitrios Pappas ⁶, Heather Litman ⁵, Kimberly Dandreo ⁵, Andrea Shapiro ⁷, Carol Connell ⁸ and Arthur Kavanaugh ⁹, ¹Albany Medical College, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Corrona, LLC, Waltham, MA, ⁶Columbia University, New York, NY, ⁷Pfizer Inc, Peapack, NJ, ⁸Pfizer Inc, Groton, CT, ⁹University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Real‑world data (RWD) complement clinical trial data in assessing long-term safety. We evaluated…
Abstract Number: 2399 • 2019 ACR/ARP Annual Meeting
Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
Carlos Sánchez-Piedra¹, María Colazo ², Rosa Roselló ³, Cristina Campos ⁴, P. Vela ⁵, Cristina Bohorquez ⁶, Carolina Pérez-García ⁷, Manuel Pombo-Suarez ⁸, Carlos Fernández-López ⁹, Dolores Ruiz-Montesinos ¹⁰, Fernando Alonso ¹¹, Federico Diaz-Gonzalez ¹² and Juan Jesús Gómez-Reino ¹³, ¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²Hospital de Burgos, Burgos, ³Hospital San Jorge, Huesca, ⁴Hospital General de Valencia, Valencia, ⁵Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ⁶Universitary Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcala de Henares, Spain, ⁷Rheumatology, Hospital del Mar, Barcelona, Catalonia, Spain, ⁸Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ¹⁰Hospital Virgen Macarena, Sevilla, ¹¹Unidad Investigación SER, Madrid, Spain, ¹²Hospital de Canarias, Tenerife, ¹³Hospital de Santiago, Santiago de Compostela
Background/Purpose: During the past 15 years, advancements in the understanding of the safety and effectiveness, as well as the expanding access and availability of biologic…
Abstract Number: 2816 • 2019 ACR/ARP Annual Meeting
An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium
Anna Helena Jonsson¹, Fan Zhang ², Gerald Watts ², Kevin Wei ¹, Deepak Rao ², Soumya Raychaudhuri ² and Michael Brenner ³, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital:, Boston
Background/Purpose: CD8 T cells represent nearly half of T cells in inflamed synovium from patients with rheumatoid arthritis (RA). Research to date has focused on…
Abstract Number: 2909 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Spencer I Danto¹, Negin Shojaee ¹, Ravi Shankar P Singh ¹, Zorayr Manukyan ², Jessica Mancuso ¹, Elena Peeva ¹, Michael Vincent ¹ and Jean Beebe ¹, ¹Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, Cambridge, MA, ²Pfizer Worldwide Research & Development, Immunology, and Inflammation Research Unit, ..
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system,…
Abstract Number: 47 • 2019 ACR/ARP Annual Meeting
Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl – Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity
Peter Sahlström ¹, Lisa Liljefors ¹, Vijay Joshua ², Natalia Sherina ¹, Radha Thyagarajan ¹, Lena Israelsson ², Ragnhild Stålesen ², Monika Hansson ³, Khaled Amara ², Ulf Reimer ⁴, Leonid Padyukov ¹, Elisabet Svenungsson ⁵, Karin Lundberg ¹, Anca Catrina ³, Lars Klareskog ³, Vivianne Malmström ² and Caroline Grönwall², ¹Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ³Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴JPT Peptide Technologies, Berlin, Germany, ⁵Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Serum anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA) display reactivity to a variety of cit-autoantigens. Studies of human ACPA mAbs have revealed that…
Abstract Number: 180 • 2019 ACR/ARP Annual Meeting
Identifying Comorbidities and Seropositivity in Rheumatoid Arthritis Patients Using Single-specialty Electronic Health Record Data
Huifeng Yun¹, Fenglong Xie ², Lang Chen ¹, Shuo Yang ¹ and Jeffrey Curtis ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham
Background/Purpose: Comorbidities are associated with worse clinical outcomes among patients with rheumatoid arthritis (RA), as does seropositive disease. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide…
Abstract Number: 250 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Chakkarin Burudpakdee ³, Lawrence Chang ², Jing He ⁴ and Mark Genovese ⁵, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Falls Church, VA, ⁴IQVIA, Plymouth meeting, PA, ⁵Stanford University, Stanford, CA
Background/Purpose: For RA patients not meeting their treat-to-target goals despite treatment with their first biologic (b)DMARD, ACR guidelines recommend switching to a different bDMARD or…
Abstract Number: 429 • 2019 ACR/ARP Annual Meeting
Concordance Between Physician and Patient Assessment of Disease Activity in Rheumatoid Arthritis Using Disease Activity Score: Phase II Results
Nelly Ziade¹, Samar Alemadi ², Mohammad Abu Jbara ³, Sahar Saad ⁴, Lina El-Kibbi ⁵, Manal Al-Mashaleh ⁶, Bassel El-Zorkany ⁷, Georges Merheb ⁸, Elie Alam ⁹, Alla Aiko ¹⁰, Jamil Messaykeh ¹¹, Nelly Salloum ¹², Amani Daher ¹, Hussein Halabi ¹³, Kamel Mroue' ¹⁴, Basel Masri ¹⁵, Humeira Badsha ¹⁶, Ghita Harifi ¹⁶ and Thurrayya Arayssi ¹⁷, ¹Saint-Joseph University, Beirut, Lebanon, ²Hamad medical corporation, Doha, Qatar, ³Jordan, Amman, Jordan, ⁴King Hamad University Hospital, Bahrain, Bahrain, ⁵Specialized Medical Center, Riyadh, Saudi Arabia, ⁶King Hussein Medical Center, Amman, Jordan, ⁷Cairo University, Cairo, Egypt, ⁸Holy Spirit University of Kaslik, Kaslik, Lebanon, ⁹Levant Hospital, Beirut, Lebanon, ¹⁰Beirut, Beirut, Lebanon, ¹¹Monla Hospital, Tripoli, Lebanon, ¹²RN, Beirut, Lebanon, ¹³King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, ¹⁴Bahman Hospital, Beirut, Lebanon, ¹⁵Jordan Hospital, Amman, Jordan, ¹⁶Dr Humeira Badsha Medical Center, Dubai, United Arab Emirates, ¹⁷Weill Cornell Medicine-Qatar, Doha, Qatar
Background/Purpose: Involving patients with rheumatoid arthritis (RA) in the assessment of their disease may increase adherence to treatment, improve disease outcomes and reduce consultation time.…
Abstract Number: 463 • 2019 ACR/ARP Annual Meeting
High-titer Rheumatoid Factor Impacts Real-life Management Outcomes of Rheumatoid Arthtitis
Cleandro Albuquerque¹, Ana Reis ², Ana Santos ³, Claiton Brenol ⁴, Ivanio Pereira ⁵, Karina Bonfiglioli ⁶, Manoel Bertolo ⁷, Maria Guimarães ⁸, Maria Sauma ⁹, Paulo Filho ¹⁰, Rina Giorgi ¹¹, Sebastião Radominski ¹², Licia Mota ¹ and Geraldo Castelar ³, ¹UnB, Brasília, Brazil, ²UniCeub, Brasília, Brazil, ³UERJ, Rio de Janeiro, Brazil, ⁴Universidade Federal do Rio Grande do Sul, Porto Alegre, ⁵UFSC, Florianópolis, Brazil, ⁶Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ⁷University of Campinas, Campinas, Brazil, ⁸UFMG, Belo Horizonte, Brazil, ⁹UFPA, Belém, Brazil, ¹⁰USP, São Paulo, Brazil, ¹¹Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil, ¹²Universidade Federal do Paraná, Curitiba, Brazil
Background/Purpose: The rheumatoid factors (RF) have established roles in rheumatoid arthritis (RA) diagnosis, prediction of disease onset and drug response, and in classifying patients as…
Abstract Number: 499 • 2019 ACR/ARP Annual Meeting
The Generation of Anti-CCP Tests Affects Diagnostic Accuracy in Rheumatoid Arthiritis: A Systematic Literature Review and Meta-Analysis
Barbara Mascialino¹, Linda Mathsson-Alm ¹, Maryam Poorafshar ¹ and Teresa Tarrant ², ¹Thermo Fisher Scientific, Uppsala, Uppsala Lan, Sweden, ²Duke School of Medicine, Division of Rheumatology and Immunology, Durham, NC
Background/Purpose: The detection of antibodies to cyclic citrullinated peptides (anti-CCP) may occur long before the onset of rheumatoid arthritis (RA) symptoms.Several versions of CCP antigen…
Abstract Number: 546 • 2019 ACR/ARP Annual Meeting
Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX
René Toes¹, Thomas Lehman ², Joshua Bryson ³, Amy Min Kim ², Sandhya Balachandar ², Sumanta Mukherjee ², Michael Maldonado ², Sean Connolly ² and Thomas Huizinga ¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Princeton
Background/Purpose: An emerging concept of “immunologic remission” in RA raises questions about the relevance of the RA autoantibody profile in patients (pts) who are otherwise…
Abstract Number: 849 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies between biologic and csDMARD-treated RA patients.Methods: We conducted an historical cohort study…
Abstract Number: 985 • 2019 ACR/ARP Annual Meeting
Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis
Tomohiro Koga¹, Tomohito Sato ², Yushiro Endo ¹, Sosuke Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Takashi Igawa ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ³, Nobuya Yoshida ⁴, Masataka Umeda ⁵, George Tsokos ⁴ and Atsushi Kawakami ⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Nagasaki University, Nagasaki, Japan, ³Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Background: CD4 + T cells are important in the pathogenesis of rheumatoid arthritis (RA), and therapies targeting the differentiation of osteoclasts are attracting attention. Calcium/calmodulin-dependent…

« Previous Page
1
…
4
5
6
7
8
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.